wenzhou gugao international trade CO.,LTD. , https://www.gugaotrade.com
Shenzhen invested 7.2 billion to build a bio-medical base
It is reported that the leading group for planning and construction of the Shenzhen Biopharmaceutical Industry Base led by Xu Zongheng, member of the Shenzhen Municipal Standing Committee and executive deputy mayor, and the Leading Group for the introduction of new and high-tech major projects have been established recently. In order to actively strive for the establishment of the Shenzhen Biopharmaceutical Industrial Base Project and to promote the development of Shenzhen's biopharmaceutical industry, the leading group for the planning and construction of the Shenzhen Biopharmaceutical Industry Base was headed by Xu Zongheng, Member of the Shenzhen Municipal Standing Committee and Executive Deputy Mayor. It is understood that the total investment in the base construction will reach 7.2 billion yuan, including a number of key industrial projects under construction, as well as the proposed pilot experimental animal center, GMP biopharmaceutical pilot test base, biomedical engineering prototype test center, and marine life. Technical product pilot bases and other industrial platforms and public technology platform projects. At present, relevant departments are stepping up efforts to formulate specific supporting policies for support and efforts to attract large-scale domestic and international biomedical enterprises to settle in Shenzhen. In the near future, the base will formally submit an application for inclusion in the national industrial base to the National Development and Reform Commission. According to the "Shenzhen National Biopharmaceutical Industry Base Development Plan", by 2010, the total annual output value of the Shenzhen biopharmaceutical industry is expected to reach 70 billion to 100 billion yuan. Among them, natural medicines, Chinese medicines and chemical medicines ranged from 35 to 46 billion yuan, biotechnology products from 17.5 to 27 billion yuan, and biomedical engineering products from 17.5 to 27 billion yuan. By then, Shenzhen will cultivate 1-2 biopharmaceutical companies with annual sales of over 10 billion yuan, 2 to 3 companies with 5 billion to 10 billion yuan, and 10 to 15 companies from 1 billion to 5 billion yuan. (High-tech Industry Herald)